GET DAILY SIGNALSLexicon Pharmaceuticals (LXRX) Holds Near $1.78 (+1% Over 30 Days) Despite -25% Quarterly Decline
Key Takeaways
- LXRX closed near $1.78, roughly flat (about +1%) over the trailing 30 days, even as shares remain down roughly 25% over the last quarter.
- Third-quarter 2026 results beat expectations, with a $0.03 per-share loss versus a $0.06 consensus estimate and revenue of $11.25 million.
- The Phase 3 SONATA-HCM trial of sotagliflozin is fully enrolled at 542 patients, with topline data expected in the first quarter of 2027.
- The ZYNQUISTA new drug application (NDA) resubmission in type 1 diabetes is now targeted for Q1 2027, supported by positive STENO1 safety data.
- Partner programs with Novo Nordisk (LX9851) and Viatris continue to generate milestone and licensing value.
- Analyst sentiment remains constructive, with a Strong Buy consensus and price targets well above current trading levels.
- For additional detail, explore Price Targets, Earnings, and Forecast pages for LXRX.
- Readers can also explore Trending AI Robots to see how automated strategies are approaching the stock.
Where LXRX Stands in the Market Right Now
Lexicon Pharmaceuticals shares have shown relative stability over the past 30 days, holding near $1.78 after a turbulent stretch. The stock touched a multi-month low in late October before rebounding on the back of third-quarter results and encouraging clinical updates. While the near-term move is modest, the longer trend remains negative: shares have declined roughly 25% over the last quarter as investors weighed regulatory timeline shifts against a catalyst-rich pipeline.
Within the small-cap biopharmaceutical space, LXRX continues to trade at a level that reflects a deeply discounted valuation relative to consensus analyst price targets. Investor attention is concentrated on binary, data-driven events slated for early 2027, which has kept day-to-day trading range-bound even amid broader sector volatility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Lexicon Pharmaceuticals (LXRX) Business Overview and Competitive Position
Lexicon Pharmaceuticals is a cardiometabolic-focused biopharmaceutical company headquartered in The Woodlands, Texas. Its commercial asset, INPEFA (sotagliflozin), is approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in certain adults with heart failure or type 2 diabetes and other risk factors.
The company's pipeline is built around sotagliflozin, a dual SGLT1 and SGLT2 inhibitor being studied in the pivotal SONATA-HCM Phase 3 trial for symptomatic hypertrophic cardiomyopathy (HCM). Lexicon is also developing pilavapadin (LX9211), a novel AAK1 inhibitor for diabetic peripheral neuropathic pain, and has licensed LX9851, a first-in-class ACSL5 inhibitor for obesity, to Novo Nordisk. Under a separate agreement, Viatris holds ex-U.S. and ex-European rights to sotagliflozin. This diversified, partnered pipeline positions Lexicon to capture milestone and royalty economics while advancing its own late-stage programs.
Recent Developments Driving LXRX
Several verified developments have shaped investor sentiment in recent weeks. The company reported third-quarter 2026 results that exceeded consensus, posting a net loss of $0.03 per share against a $0.06 expected loss, with revenue of $11.25 million. The quarter also brought meaningful clinical progress: the SONATA-HCM study surpassed its enrollment target with 542 patients, and topline data remains on track for the first quarter of 2027.
On the regulatory front, Lexicon confirmed that the ZYNQUISTA NDA resubmission for type 1 diabetes is now anticipated in the first quarter of 2027, a timeline that has slipped from earlier guidance. The company cited the work required to bring investigator-generated STENO1 safety data to regulatory submission standards. Positively, STENO1 data showed diabetic ketoacidosis rates that were low and comparable to standard of care, addressing a key FDA safety concern. Lexicon also received its third $10 million LX9851 milestone payment from Novo Nordisk during the quarter.
Analyst activity has been supportive. H.C. Wainwright maintained a Buy rating with a $6.00 price target, while Citi maintained a Buy rating with a $3.10 target, reflecting a consensus that values the pipeline well above the current share price. One thing that stands out here is how the data beats align with broader pipeline momentum.
2026 Outlook and What Investors Should Watch
Looking ahead, the most significant catalyst for LXRX is the SONATA-HCM topline readout expected in the first quarter of 2027, which has the potential to redefine the company's commercial opportunity in HCM. Equally important is the ZYNQUISTA NDA resubmission timeline, where execution against the updated first-quarter 2027 target will be closely scrutinized given prior slippage.
Investors should also monitor progress on the LX9851 program with Novo Nordisk and any potential partnership for pilavapadin, which management has described as Phase 3-ready in diabetic peripheral neuropathic pain. Financial durability remains a factor, with roughly $183 million in cash and investments reported at the end of the third quarter and 2026 operating expense guidance of $100–110 million. Regulatory developments, competitive dynamics in HCM and obesity, and broader risk appetite for pre-commercial biotech names will all influence how the stock trades into the next catalyst window. I’m watching this closely as the data readouts approach.
Using Tickeron’s AI Tools for Deeper Analysis
In my own review of LXRX, I turned to Tickeron’s AI Trading Bots to test how different algorithmic strategies have performed around similar catalyst-driven biotech names. These tools help surface patterns in volatility and momentum that complement traditional fundamental work. For investors tracking names like this one, they offer a practical way to cross-check positioning without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LXRX in +20.27% Uptrend, growing for three consecutive days on November 06, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LXRX advanced for three days, in 196 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LXRX's RSI Oscillator exited the oversold zone, 27 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on LXRX as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for LXRX just turned positive on October 28, 2026. Looking at past instances where LXRX's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for LXRX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
LXRX broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LXRX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.538) is normal, around the industry mean (3.482). P/E Ratio (-11.125) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.570) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. LXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in discovery and development of breakthrough treatments for human disease
Industry Biotechnology
Advertisement